MET and non-small cell lung carcinoma: According to the latest National Comprehensive Cancer Network (NCCN) guidelines for NSCLC (3rd Edition, 2021), the genes with driver mutations include: epidermal growth factor receptor (EGFR); anaplastic lymphoma kinase (ALK), c-ros oncogene 1 receptor tyrosine kinase (ROS1); human epidermal growth factor receptor 2 (HER2); mesenchymal to epithelial transition factor (MET); v-raf murine sarcoma viral oncogene homolog B1 (BRAF); Kirsten rat sarcoma (KRAS); rearrangement during transfection (RET); and neurotrophic tyrosine receptor kinase (NTRK) [5].